JANX

SEC source: 0001415889-25-000554 · form4-01032025_050101.xml · derivative · entry 7

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,000

Underlying: Common Stock · 63,000 shares

Expires 2035-01-01

F8 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 6

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,139

F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.

F7 · price: The weighted average sale price for the transaction reported was $57.365 and the range of prices were between $57.35 and $57.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 5

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,339

F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.

F6 · price: The weighted average sale price for the transaction reported was $56.7778 and the range of prices were between $56.33 and $57.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 4

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,339

F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.

F5 · price: The weighted average sale price for the transaction reported was $55.7587 and the range of prices were between $55.24 and $56.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 3

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,783

F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.

F4 · price: The weighted average sale price for the transaction reported was $54.5111 and the range of prices were between $54.21 and $55.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 2

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,551

F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.

F3 · price: The weighted average sale price for the transaction reported was $53.7582 and the range of prices were between $53.20 and $54.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-25-000554 · form4-01032025_050101.xml · nonDerivative · entry 1

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,473

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.

SEC source: 0001415889-25-000675 · form4-01032025_080107.xml · derivative · entry 2

Campbell David Alan · CIK 0001864158 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,500

Underlying: Common Stock · 283,500 shares

Expires 2035-01-01

F2 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001415889-25-000675 · form4-01032025_080107.xml · nonDerivative · entry 1

Campbell David Alan · CIK 0001864158 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 298,054

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.

SEC source: 0001415889-25-000676 · form4-01032025_080109.xml · derivative · entry 2

Winter Charles M. · CIK 0001960264 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,500

Underlying: Common Stock · 80,500 shares

Expires 2035-01-01

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2026 and the balance will vest in equal monthly installments thereafter over a three year period.

SEC source: 0001415889-25-000676 · form4-01032025_080109.xml · nonDerivative · entry 1

Winter Charles M. · CIK 0001960264 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,288

F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments beginning on January 1, 2026.

F2 · balance_after: Includes 1,297 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2021, 1,644 shares acquired under the Plan on May 13, 2022, 2,401 shares acquired under the Plan on May 15, 2023, 2,834 shares acquired under the Plan on May 15, 2024 and 1 share acquired under the Plan on November 15, 2024.

SEC source: 0001415889-24-030211 · form4-12272024_081201.xml · nonDerivative · entry 1

Campbell David Alan · CIK 0001864158 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 217,054

F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.

F2 · price: The weighted average sale price for the transaction reported was $56.1922 and the range of prices were between $56.00 and $56.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-029989 · form4-12202024_111213.xml · derivative · entry 4

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,999

Underlying: Common Stock · 1 shares

Expires 2033-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% of the shares subject to the option vested on January 1, 2024 and the balance vests in equal monthly installments thereafter over a three year period.

SEC source: 0001415889-24-029989 · form4-12202024_111213.xml · derivative · entry 3

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,870

Underlying: Common Stock · 9,880 shares

Expires 2032-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares subject to the option vested on January 1, 2023 and the balance vests in equal monthly installments thereafter over a three year period.

SEC source: 0001415889-24-029989 · form4-12202024_111213.xml · nonDerivative · entry 2

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,473

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-029989 · form4-12202024_111213.xml · nonDerivative · entry 1

Meyer Andrew Hollman · CIK 0001864159 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,472

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-028203 · form4-12032024_081201.xml · nonDerivative · entry 1

Campbell David Alan · CIK 0001864158 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 242,054

F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.

SEC source: 0001415889-24-027905 · form4-11272024_081102.xml · nonDerivative · entry 2

Campbell David Alan · CIK 0001864158 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 257,054

F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.

F3 · price: The weighted average sale price for the transaction reported was $52.0385 and the range of prices were between $51.89 and $52.385. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-027905 · form4-11272024_081102.xml · nonDerivative · entry 1

Campbell David Alan · CIK 0001864158 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 263,773

F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.

F2 · price: The weighted average sale price for the transaction reported was $51.4322 and the range of prices were between $50.89 and $51.885. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-026385 · form4-11082024_121119.xml · nonDerivative · entry 1

CAPPS VICKIE L · CIK 0001248190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,348

F1 · kind: Represents receipt of securities in a pro rata, in-kind distribution of securities, by ABV SPV I GP LLC, of which Reporting Person is a member.

SEC source: 0001415889-24-026386 · form4-11082024_121151.xml · nonDerivative · entry 1

Gujrathi Sheila · CIK 0001575202 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,139

F1 · kind: Represents receipt of securities in a pro rata, in-kind distribution, and not a purchase of securities, by ABV SPV I GP LLC, of which Reporting Person is a member.

SEC source: 0001415889-24-025792 · form4-10302024_071002.xml · nonDerivative · entry 2

Campbell David Alan · CIK 0001864158 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 282,054

F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.

F3 · price: The weighted average sale price for the transaction reported was $53.9412 and the range of prices were between $53.58 and $54.445. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-025792 · form4-10302024_071002.xml · nonDerivative · entry 1

Campbell David Alan · CIK 0001864158 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 293,157

F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.

F2 · price: The weighted average sale price for the transaction reported was $53.2237 and the range of prices were between $52.5801 and $53.575. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 25

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, L.P.

Disclosed balance after: 2,115,373

F11 · kind: Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024.

F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 24

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 401,321

F11 · kind: Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024.

F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 23

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,071,799

F11 · kind: Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024.

F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 22

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, L.P.

Disclosed balance after: 2,668,592

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 21

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 506,278

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 20

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,613,623

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 19

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures SPV I, L.P.

Disclosed balance after: 2,684,380

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 18

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Avalon BioVentures I, LP

Disclosed balance after: 509,273

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 17

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,629,085

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.

SEC source: 0001415889-24-025502 · form4-10222024_041001.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 9,317,246

F1 · kind: Shares purchased in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 33

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,072

Underlying: Common Stock · 237 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: Immediately exercisable.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 32

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,142

Underlying: Common Stock · 348 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: Immediately exercisable.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 31

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,142

Underlying: Common Stock · 348 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: Immediately exercisable.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 30

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,940

Underlying: Common Stock · 836 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: Immediately exercisable.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 16

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,371

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.97 to $50.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 15

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,214

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 14

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,977

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 13

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,629

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 12

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,281

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 29

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,309

Underlying: Common Stock · 1,407 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: Immediately exercisable.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 28

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,490

Underlying: Common Stock · 2,070 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: Immediately exercisable.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 27

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,490

Underlying: Common Stock · 2,070 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: Immediately exercisable.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · derivative · entry 26

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,776

Underlying: Common Stock · 4,968 shares

Expires 2027-07-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: Immediately exercisable.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 11

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,445

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.76 to $51.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 10

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,402

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 9

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,995

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.

SEC source: 0001415889-24-025436 · form4-10182024_101021.xml · nonDerivative · entry 8

Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner

Avalon BioVentures I, LP · CIK 0001873935 · 10% owner

Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner

Lichter Jay · CIK 0001376355 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,925

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · ownership.direct: The securities are directly held by Mr. Lichter.